McKesson Yönetim

Yönetim kriter kontrolleri 3/4

McKesson CEO'su Brian Tyler, Apr2019 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 19.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.062% ine doğrudan sahiptir ve bu hisseler $ 49.36M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 3.2 yıldır.

Anahtar bilgiler

Brian Tyler

İcra Kurulu Başkanı

US$19.0m

Toplam tazminat

CEO maaş yüzdesi	7.8%
CEO görev süresi	5.6yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Brian Tyler'un ücretlendirmesi McKesson'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$3b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	US$19m	US$1m	US$3b
Dec 31 2023	n/a	n/a	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	US$20m	US$1m	US$4b
Dec 31 2022	n/a	n/a	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	US$18m	US$1m	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	n/a	n/a	-US$5b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	US$15m	US$1m	-US$5b
Dec 31 2020	n/a	n/a	-US$4b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$922m
Mar 31 2020	US$15m	US$1m	US$906m
Dec 31 2019	n/a	n/a	-US$905m
Sep 30 2019	n/a	n/a	-US$626m
Jun 30 2019	n/a	n/a	US$601m
Mar 31 2019	US$13m	US$929k	US$33m

Tazminat ve Piyasa: Brian 'nin toplam tazminatı ($USD 19.00M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.77M ).

Tazminat ve Kazançlar: Brian 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Brian Tyler (57 yo)

5.6yrs

Görev süresi

US$18,997,543

Tazminat

Mr. Brian S. Tyler, Ph D., has been an Independent Director at Republic Services, Inc. since April 1, 2021. He served as Chairman of Supervisory Board at McKesson Europe AG since August 9, 2018 until 2022....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Brian Tyler	CEO & Director	5.6yrs	US$19.00m	0.062% $ 49.4m
Britt Vitalone	Executive VP & CFO	6.8yrs	US$6.78m	0.011% $ 9.1m
Michele Lau	Executive VP & Chief Legal Officer	less than a year	US$8.81m	0.00011% $ 87.5k
LeAnn Smith	Executive VP & Chief Human Resources Officer	1.9yrs	US$3.54m	0.0016% $ 1.3m
Thomas Rodgers	Executive VP and Chief Strategy & Business Development Officer	4.4yrs	US$3.18m	0.0020% $ 1.6m
Napoleon Rutledge	Senior VP	2.7yrs	Veri yok	0.0015% $ 1.2m
Francisco Fraga	Executive VP	1.1yrs	Veri yok	Veri yok
Rachel Rodriguez	Vice President of Investor Relations	no data	Veri yok	Veri yok
Pete Slone	Senior Vice President of Corporate Public Affairs	9.4yrs	Veri yok	Veri yok
Kirk Kaminsky	President of The US Pharmaceutical & Specialty Solutions Business	5.6yrs	Veri yok	Veri yok
Paul Smith	Senior Vice President of Taxes	no data	Veri yok	Veri yok
Kevin Emerson	Senior Vice President of Finance Operations	2.7yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: 0JZU 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Brian Tyler	CEO & Director	5.6yrs	US$19.00m	0.062% $ 49.4m
Donald Knauss	Independent Chairman of the Board	10.1yrs	US$555.22k	0.0016% $ 1.3m
Maria Martinez	Independent Director	5.1yrs	US$335.08k	0.00027% $ 214.7k
Dominic Caruso	Independent Director	6.2yrs	US$336.21k	0.00027% $ 214.7k
Deborah Dunsire	Director	less than a year	Veri yok	Veri yok
James Hinton	Independent Director	2.8yrs	US$315.08k	Veri yok
Webster Dunbar	Independent Director	2.6yrs	US$315.08k	Veri yok
Kathleen Wilson-Thompson	Independent Director	2.8yrs	US$315.08k	Veri yok
Richard Carmona	Independent Director	3.2yrs	US$313.71k	Veri yok
Kevin Ozan	Independent Director	less than a year	US$139.34k	0.000010% $ 8.0k
Bradley Lerman	Independent Director	6.6yrs	US$328.71k	Veri yok

3.2yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0JZU 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

McKesson Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

High number of new directors

Mckesson Corporation Elects Kevin Ozan as New Director

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

McKesson Corporation Announces Management Changes

Recent updates

Investor sentiment improves as stock rises 16%

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

New minor risk - Earnings quality

Second quarter 2025 earnings released: EPS: US$1.87 (vs US$4.95 in 2Q 2024)

First quarter dividend of US$0.71 announced

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2025

McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

McKesson Corporation to Report Q2, 2025 Results on Nov 06, 2024

First quarter 2025 earnings released: EPS: US$7.05 (vs US$7.07 in 1Q 2024)

Fourth quarter dividend increased to US$0.71

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on October 1, 2024

McKesson Corporation to Report Q1, 2025 Results on Aug 07, 2024

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

Upcoming dividend of US$0.62 per share

Full year 2024 earnings released: EPS: US$22.54 (vs US$25.25 in FY 2023)

Third quarter dividend of US$0.62 announced

McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024

McKesson Corporation to Report Q4, 2024 Results on May 07, 2024

Upcoming dividend of US$0.62 per share

Third quarter 2024 earnings released: EPS: US$4.45 (vs US$7.71 in 3Q 2023)

Second quarter dividend of US$0.62 announced

Mckesson Corporation Declares Quarterly Dividend, Payable on April 1, 2024

High number of new directors

McKesson Corporation Reportedly Seeks Buyers for Canada's Rexall Pharmacy

McKesson Corporation (NYSE:MCK) acquired Compile, Inc.

Mckesson Corporation Elects Kevin Ozan as New Director

McKesson Corporation to Report Q3, 2024 Results on Feb 07, 2024

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

Upcoming dividend of US$0.62 per share at 0.5% yield

Second quarter 2024 earnings released: EPS: US$4.93 (vs US$6.51 in 2Q 2023)

McKesson Corporation Announces Management Changes

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2024

McKesson Corporation to Report Q2, 2024 Results on Nov 01, 2023

Upcoming dividend of US$0.62 per share at 0.6% yield

First quarter 2024 earnings released: EPS: US$7.07 (vs US$5.31 in 1Q 2023)

McKesson Corporation Raises Quarterly Dividend, Payable on October 2, 2023

McKesson Corporation to Report Q1, 2024 Results on Aug 02, 2023

McKesson Unveils New Private Brand of Over-the-Counter Pharmacy Products

McKesson Corporation, Annual General Meeting, Jul 21, 2023

McKesson Corporation, Annual General Meeting, Jul 21, 2023

Upcoming dividend of US$0.54 per share at 0.5% yield

Full year 2023 earnings released: EPS: US$25.25 (vs US$7.35 in FY 2022)

Upcoming dividend of US$0.54 per share at 0.6% yield

Third quarter 2023 earnings released: EPS: US$7.71 (vs US$0.046 loss in 3Q 2022)

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on April 3, 2023

McKesson Corporation to Report Q3, 2023 Results on Feb 01, 2023

Upcoming dividend of US$0.54 per share

High number of new directors

Second quarter 2023 earnings released: EPS: US$6.47 (vs US$1.73 in 2Q 2022)

McKesson Corporation Declares Quarterly Dividend, Payable on January 3, 2023

McKesson Corporation to Report Q2, 2023 Results on Nov 01, 2022

McKesson Corporation (NYSE:MCK) signed a definitive agreement to acquire Rx Savings, LLC for approximately $880 million.

McKesson Corporation (NYSE:MCK) signed a definitive agreement to acquire Rx Savings, LLC for approximately $880 million.

McKesson Corporation Appoints Leann B. Smith as Next Chief Human Resources Officer

Upcoming dividend of US$0.54 per share

First quarter 2023 earnings released: EPS: US$5.25 (vs US$3.13 in 1Q 2022)

McKesson Corporation Raises Quarterly Dividend, Payable on October 3, 2022

McKesson Corporation to Report Q1, 2023 Results on Aug 03, 2022

McKesson Corporation, Annual General Meeting, Jul 22, 2022

Executive VP & CFO recently sold US$564k worth of stock

Executive VP & CFO recently sold US$1.4m worth of stock

Upcoming dividend of US$0.47 per share

Full year 2022 earnings released: EPS: US$7.35 (vs US$28.26 loss in FY 2021)

High number of new directors

McKesson Corporation to Report Q4, 2022 Results on May 05, 2022

McKesson Corporation Elects W. Roy Dunbar as New Director

AmerisourceBergen, Cardinal Health and McKesson Approve Opioid Settlement Agreement

McKesson Corporation Announces Executive Changes